Oxford Drug Design

Oxford Drug Design is an innovative company spun-out from Professor Graham Richards' group at the University of Oxford. The company has developed rapid, state-of-the-art virtual screening and ligand analogue searching technologies to help with the drug discovery process. Utilising this technology platform the company has developed novel antibiotic programmes.

Our Team

Prof. W. Graham Richards CBE FRS

Chairman and Founder

Graham served as Chairman of the Department of Chemistry at Oxford University. Throughout his career, he has been involved in the commercialization of technologies where he was a director of the University of Oxford's technology transfer company. He was also involved with the Wellcome Trust in a similar capacity. He co-founded Oxford Molecular Group plc, InhibOx Ltd. and Oxford Drug Design Ltd. He was a main board director, now venture partner, of IP Group plc, the listed intellectual property commercialization company.

Prof. Paul Finn

Chief Executive Officer

Paul completed his undergraduate degree at St Peter's College, Oxford and his biochemistry Ph.D. at the University of Manchester. He has worked as a computational chemist for SmithKline Beecham and Pfizer. Paul was group director of R&D at TopoTarget. He led the histone deacetylase inhibitor programme through discovery and pre-clinical development, and is co-inventor of Belinostat, which was approved by the FDA for the treatment of T-cell lymphoma in 2014. 

Dr. Michael Charlton

Head of Drug Discovery

After a degree and Ph.D. at the University of St. Andrews, Michael worked as a computational chemist at Zeneca Specialties. He then set up the computational chemistry group at Evotec before moving to Chroma Therapeutics as head of computational chemistry. He managed the early stage of one of the inflammation projects and worked on reviewing new drug targets. He also sat on the project review team, which made key decisions on project direction. Michael joinied InhibOx, now Oxford Drug Design, in 2013. Michael manages our antibiotic drug discovery projects.

Dr. Grace Edmund

Senior Computational Chemist

Grace completed her undergraduate degree at the University of Durham. She completed her masters year while working as an industrial trainee at Pfizer, Sandwich. She completed her Ph.D in computational chemistry at the University of Surrey modelling species selectivity in cytochrome P450 enzymes. Grace joined InhibOx, now Oxford Drug Design as a computational chemist in 2015. Grace leads our computational effort on the aminoacyl tRNA synthetase drug discovery programme.

Dr. Jerome Wicker


Jerome completed his Undergraduate Master's degree in Chemistry at Worcester College, Oxford, and continued on there to undertake a D.Phil in Inorganic Chemistry, during which he developed a descriptor to capture molecular conformational flexibility. Jerome joined Oxford Drug Design in 2017 as cheminformatician and scientific programmer, with responsibility for maintaining and improving our databases and virtual screening tools, while also developing our machine-learning capabilities.

Marco Albanese

Early Stage Researcher

Marco completed his Undergraduate Master's degree in Pharmaceutical Chemistry and Technology at the University of Salerno. He did a joint Master’s thesis in computer-aided drug design in collaboration with the University of Eastern Finland designing potential anti-inflammatory and anti-cancer compounds. Marco joined Oxford Drug Design in 2018 as a Ph.D student, part of the CARTNET project (Combating Antimicrobial Resistance Training Network), with the aim to develop novel antibacterial agents targeting Histidine Kinases.

Scientific Advisory Board

James B. Kahn, M.D. FIDSA

Dr. Kahn has deep and extensive knowledge of antibacterial drug development. He is Board-certified in both I.M. and I.D. After 18 years in the solo private practice of I.D. Medicine, James was recruited by Johnson & Johnson's Ortho-McNeil Pharmaceutical to be the first Director of their new I.D. Franchise. In addition to running numerous clinical trials for the antimicrobial FLOXIN, he also took over the clinical development of LEVAQUIN and was responsible for the sNDAs that led to 8 new FDA-approved indications. He proposed and then developed the higher-dose, shorter-course approach to accelerate pathogen eradication and reduce anti-bacterial exposure.
James is the founder and principal of JBK Strategic Consultations, LLC, a small firm providing Infectious Disease expertise to the Pharmaceutical, Venture Capital, and Medico-legal communities. He attends numerous national and international I.D. meetings and maintains close personal and professional contacts with many US and global opinion leaders.

Prof. David Livermore 

David Livermore gained his BSc in 1978 and his PhD in 1983. He worked at the London Hospital Medical College from 1980 until 1997 when he joined the Health Protection Agency (now Public Health England), becoming Director of its Antibiotic Resistance Monitoring and Reference Laboratory in 1998. In October 2011 he moved to become Professor of Medical Microbiology at the University of East Anglia but still retains sessions at Public Health England as its Lead on Antibiotic Resistance. He has broad interests on the mechanisms, evolution and dissemination of antibiotic resistance and its relationship to antibiotic usage. He is very active in the field of antibiotics and resistance and is a member of the UK Government's Antimicrobial Resistance & Healthcare Infections Advisory Committee. He publishes and speaks widely on resistance and has edited for several journals including Journal of Antimicrobial Chemotherapy, Journal of Medical Microbiology and International Journal of Antimicrobial Agents.
Outside of work he is a keen walker and, in 2016, completed a 3000-mile route that has taken him right around the perimeter of England.

Dr. Pamela Brown

Pam has over 30 years experience in anti-infective drug discovery, initially gained at GlaxoSmithKline and legacy companies, leading medicinal chemistry teams in hit to lead and lead optimisation phases of drug discovery. In 2008, Pam joined BioFocus, where she co-led integrated drug discovery projects towards a variety of targets. Pam joined Cantab Anti-infectives as director of medicinal chemistry in 2012, leading the medicinal chemistry team towards novelpolymyxins, resulting in a commercial deal with Spero Therapeutics in 2016 and the selection of a preclinical candidate in 2017. Since 2017, Pam has operated as an independent consultant in antibacterial drug discovery and medicinal chemistry with clients in the UK, Europe and the US. Pam has over 35 publications in patents and peer-reviewed journals on the design and synthesis of antibacterial agents in a variety of antibacterial classes including carbapenems, pleuromutilins, tRNA synthetase inhibitors, topoisomerase inhibitors and polymyxins. Pam holds a degree in Chemistry from Imperial College, London, and is a Fellow of the Royal Society of Chemistry. 


Oxford Drug Design
Oxford Centre for Innovation
New Road


Email: contactus@oxforddrugdesign.com
Phone: +44 (0) 1865 261 468

Follow Us

We use cookies to give you the best experience. Read our privacy policy for more information.